Vineet Datta, Senior Director of Global Strategy at Datar Cancer Genetics Limited, shared a post on LinkedIn:
“Early cancer detection saves lives.
In 2025, updates to NHS screening programmes in England have focused on targeting high-risk groups for cervical, bowel, and lung cancers, with an aim to boost earlier diagnosis where it counts most. These shifts are backed by evidence, but rising rates of cancers in younger adults highlight the urgency for ongoing awareness—especially since many aggressive cancers still lack routine screening programmes.
Assays like MCED (multi-cancer early detection) tests aim to reduce and eventually downstage late-stage diagnoses, but clinical validity remains key: tests must be reproducible, accurate, and add actionable clinical utility.
I am delighted to be participating in the International SOS Foundation Asia Health, Wellness and Security Conference 2025 on 25-26 November in Hyderabad. If you have questions about optimising cancer screening within your organisation or are looking to navigate the new guidelines/ technologies, let’s connect. Early action and regular engagement with evidence-based screening can be life-saving.”
More posts featuring Vineet Datta.